Finorpa
Finorpa is a Lille-based French regional investment firm founded in 1984 that manages three funds providing equity and quasi-equity capital (€150k–€1M tickets) to SMEs and healthtech startups in Hauts-de-France and nationally, with ~100 active portfolio companies built over 2,000 cumulative financings.
- Company typePrivate
- Founded1984
- HeadquartersLens, France
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Finorpa does
Finorpa is a France-based regional investment company (Société de Capital-Risque) founded in 1984 and headquartered in Lille, operating in the Hauts-de-France region. It manages three distinct fund vehicles: Finorpa SCR, a generalist equity and quasi-equity fund investing €150k–€1M per transaction in SMEs across creation, development, and transmission stages; Captech Santé, a €26M specialist healthtech venture capital fund launched in early 2022 covering biotech, medtech, e-santé, and nutrition from seed to Series A; and Hauts-de-France Avenir TPE PME, a regional co-investment fund providing up to €500k for micro-SME development and acquisition. The firm is AMF-regulated (GP1600020) and maintains a mixed public-private shareholder structure, with offices in Lille, Saint-Omer, and Amiens.
The company's revenue model is based on equity investment returns (capital gains on exits) and portfolio dividend income from approximately 100 active portfolio companies, built up from roughly 2,000 cumulative financings over its 40-year history. Finorpa is not a technology company and operates no proprietary platform; rather, its value proposition rests on long-term regional anchoring, board representation, co-investment syndication (with Bpifrance, EIC Fund, Finovam, Sopromec, Hauts-de-France Avenir TPE PME, regional councils), and specialized sector expertise delivered through its Captech Santé team. Deal flow is generated through ecosystem partnerships with incubators (EuraTechnologies), chambers of commerce (CCI Grand Lille), technology transfer offices, universities, and the Connexion Finorpa entrepreneur community of 100+ portfolio executives. Recent 2025–2026 investment activity spans medtech (Lattice Medical €43M Series B), biotech (Genoskin $8.7M Series A), nutrition (Verley €38M Series A), SaaS (Mariloo), food manufacturing (France Cake Tradition), and childcare (Naturel Kid), demonstrating active capital deployment across stages and verticals.
Finorpa firmographics
Firmographics- Name
- Finorpa
- Legal name
- Finorpa SCR
- Website
- https://finorpa.fr
- Company type
- Private
- Founded year
- 1984
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Finorpa is a Lille-based French regional investment firm founded in 1984 that manages three funds providing equity and quasi-equity capital (€150k–€1M tickets) to SMEs and healthtech startups in Hauts-de-France and nationally, with ~100 active portfolio companies built over 2,000 cumulative financings.
- Ownership category
- akta.pro rank
Finorpa industry classification
Industry- Product category
- Venture Capital and Private Equity
- NAICS
- Open-End Investment Funds (525910)
- SIC
- Miscellaneous Business Credit Institution (6159)
- akta.pro primary industry
- Independent Venture Debt Funds / Platforms (FSANAIAB)
- akta.pro secondary industry
- SME Term Loans & Growth Capital (FSAKAGAB)
Keywords
Where Finorpa is headquartered
LocationHeadquarters
- HQ city
- Lens
- HQ country
- France
- HQ region
- Europe
Offices3 records
Markets served
Finorpa business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Equity Investment Returns: Finorpa generates returns through capital gains realized upon exit of equity and quasi-equity investments in portfolio companies. As a long-term investor, the fund holds minority stakes in SMEs and shares in their growth trajectory from creation through transmission phases. Returns are realized via trade sales, IPOs, or buyouts.
- Portfolio Dividends and Income: The fund may receive dividend income from its approximately 100 active portfolio companies, generating recurring cash flow alongside capital appreciation from equity positions.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Finorpa SCR: Equity/quasi-equity investments from €150k to €1M |
| Other | Multi-year contract | Captech Santé: Seed to Series A investments in health tech |
| Other | Multi-year contract | HDF Avenir TPE PME: Co-investment up to €500k for TPE/PME |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
Finorpa product offering
Product offeringCore offering
Finorpa provides equity and quasi-equity financing to small and medium-sized enterprises in France through three investment funds: Finorpa SCR (generalist SME fund, €150k–€1M per transaction), Captech Santé (specialist venture capital for healthtech deeptech, seed to Series A), and Hauts-de-France Avenir TPE PME (regional co-investment fund for micro-SMEs, up to €500k). The company also supports portfolio companies through board representation, strategic advisory, and a network of more than 100 portfolio entrepreneurs.
Product overview
Finorpa is an investment fund management company managing three distinct funds: Finorpa SCR (the main generalist fund investing equity and quasi-equity in SMEs), Captech Santé (a specialist health technology venture capital fund), and Hauts-de-France Avenir TPE PME (a regional co-investment fund for micro-enterprises). The company also operates Connexion Finorpa, a networking community for its portfolio entrepreneurs. Investment activities span capital risk, capital development, and capital transmission across sectors including industry, services to industry, and digital, with investment amounts ranging from 150k€ to 1M€.
Differentiator
Problem solved
Functional benefit
Brands
- Finorpa SCR: Generalist equity and quasi-equity investment fund for PME and potential-driven companies
- Captech Santé
- Hauts-de-France Avenir TPE PME
Products and services
- Finorpa SCR The main investment fund of Finorpa, providing equity and quasi-equity financing of €150k to €1M per transaction to SMEs and growth companies in Hauts-de-France. Backed by a diverse public-private shareholder base, it operates as a long-term regional investor across creation, development, and transmission phases.
- Captech Santé A specialist venture capital fund for health technologies, investing from seed to Series A stages across four verticals: biotech, medtech, e-santé, and nutrition. The first French expert fund at seed stage alongside regional generalist funds, providing active strategic support including governance, clinical development, regulatory strategy, market access, and industrialization.
- Hauts-de-France Avenir TPE PME A regional co-investment fund providing equity/quasi-equity financing up to €500k for the development and acquisition of TPE and PME companies in Hauts-de-France. Operates alongside private co-investors (investment funds, family offices, business angels).
Quantifiable outcome
- 2,000 companies financed over ~40 years
- +3 more outcomes
Companies that use Finorpa
Customer profileNamed customers7 records
Segments3 records
Ideal customer profiles3 records
Finorpa technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Finorpa partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- EuraTechnologiescoreLeading regional tech incubator in Lille. Mariloo was incubated at Euratechnologies. Finorpa sources deal flow through the incubator ecosystem and supports incubated startups with growth capital.
- CCI Grand Lille (Chambre de Commerce et d'Industrie)coreChamber of Commerce and Industry for Greater Lille. Olivier Nuns previously worked at CCI Grand Lille as Manager Développement Entreprises. The CCI serves as a key ecosystem partner for SME support and deal flow generation.
- Réseau EntreprendreminorEntrepreneur support network operating in Hauts-de-France. Finorpa participates in the regional entrepreneurial ecosystem as a partner and potential investor for Réseau Entreprendre members seeking growth capital.
- France InvestminorFrench private equity industry association. Finorpa is a member, aligning with national industry standards and best practices in investment management.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
Finorpa competitors and assessment
Company assessmentBroad incumbents
- Bpifrance: France's national public investment bank with €40B+ AUM. Operates across SME equity, venture capital, and innovation funding, frequently co-investing with Finorpa (e.g., Lattice Medical, France Cake Tradition). A larger, broader incumbent in the same regional SME space.
- Eurazeo: Major French private equity firm with €35B+ AUM spanning venture, growth, and buyout. While larger and more national/international, it competes for some of the same mid-market French SME equity deals.
- Sofinnova Partners: Leading European life sciences VC firm. Co-invested with Captech Santé in Verley. While much larger and life-sciences-specialized, it competes for similar healthtech deals at Series A.
- Siparex: Independent French PE/VC group with €2.5B+ AUM operating across regional funds, including SME equity, transmission, and innovation. Comparable multi-fund regional platform structure.
Direct peers
- Nord France Amorçage: Regional seed fund for Hauts-de-France that co-invested with Finorpa in Lattice Medical. Closest geographic and stage peer, focusing on regional seed/early-stage deals with similar public-private backing.
- Finovam Gestion: Regional investment fund based in Nord-Pas-de-Calais co-investing with Finorpa in Mariloo. Similar regional SME equity mandate and co-investment thesis, making it a directly comparable peer.
- Go Capital: French regional VC firm with multiple regional funds and ~€350M AUM. Operates with similar SME equity/deeptech thesis across regions including the West of France—comparable structure and stage focus.
- NCI (Nord Capital Investissement): Nord-Pas-de-Calais regional investment firm supporting SME development and transmission. Highly comparable regional mandate, ticket size, and co-investment orientation.
Emerging players
- Alven: Paris-based early-stage VC firm leading rounds in French tech and digital health (e.g., led Verley's €38M Series A alongside Captech Santé). Comparable venture-stage focus with national reach.
Regional players
- Capital Grand Est: Regional investment fund supporting SME development in the Grand Est region. Operates a comparable regional public-private model with similar ticket sizes and transmission/development mandates.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Finorpa social profiles
Digital presenceFinorpa financial estimates
Financial estimateRevenue estimate
Valuation estimate
Finorpa leadership team
Management profileNumber of profiles
Profiles8 records
Finorpa subsidiaries and ownership
Company hierarchySubsidiaries2 records
Finorpa funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Finorpa M&A and investment
M&A and investmentM&A1 record
Investments99 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Finorpa
What does Finorpa do?
Finorpa provides equity and quasi-equity financing to small and medium-sized enterprises in France through three investment funds: Finorpa SCR (generalist SME fund, €150k–€1M per transaction), Captech Santé (specialist venture capital for healthtech deeptech, seed to Series A), and Hauts-de-France Avenir TPE PME (regional co-investment fund for micro-SMEs, up to €500k). The company also supports portfolio companies through board representation, strategic advisory, and a network of more than 100 portfolio entrepreneurs.
Is Finorpa a public or private company?
Finorpa is a private company. It is classified as unknown and is currently operating.
When was Finorpa founded?
Finorpa was founded in 1984. It employs 11 to 50 people.
Where is Finorpa based?
Finorpa is headquartered in Lens, France, in the Europe region.
How does Finorpa make money?
Two revenue lines are on record. Equity Investment Returns are the primary driver. The others are portfolio Dividends and Income.
Who are Finorpa's main competitors?
Broad incumbents on record are Bpifrance, Eurazeo, Sofinnova Partners and Siparex. Direct peers are Nord France Amorçage, Finovam Gestion, Go Capital and NCI (Nord Capital Investissement). Alven is listed as an emerging player. Capital Grand Est is listed as a regional player.
Does Finorpa have an API?
No public API is recorded for Finorpa.
What industry is Finorpa in?
Finorpa's product category is Venture Capital and Private Equity. Its primary akta.pro industry code is FSANAIAB, Independent Venture Debt Funds / Platforms, with a secondary code of FSAKAGAB, SME Term Loans & Growth Capital. Its NAICS code is 525910 and its SIC code is 6159.